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Objective: The collaborative care model is
recommended for depression in adults with a chronic
physical health problem like diabetes. We sought to
systematically assess the effect of collaborative care on
depression and glycaemia in adults with comorbid
depression and diabetes to inform guidelines and
practice.
Design: Systematic review and meta-analysis.
Data sources: We searched PubMed, Scopus,
Cochrane Library, CINAHL, Health Source Nursing,
MEDLINE, PsychINFO and reference lists of retrieved
articles published before August 2013.
Inclusion criteria: Randomised controlled trials
(RCTs) on collaborative care (ie, coordinated
multidisciplinary model of care) for depression that
reported the effects on depression and glycaemic
outcomes in adults with comorbid clinically relevant
depression and diabetes were eligible.
Data extraction and analysis: Data on the mean
difference in depression and glycaemic outcomes were
extracted and pooled using random effects
meta-analysis.
Results: Seven RCTs included for review reported
effects on depression outcomes in 1895 participants,
and glycated haemoglobin (HbA1c) level in 1556
participants. Collaborative care significantly improved
the depression score (standardised mean difference
was −0.32 (95% CI −0.53 to −0.11); I2=79%) and
HbA1c level (weighted mean difference was −0.33%
(95% CI −0.66% to −0.00%); I2=72.9%) compared
with control conditions. Depression remission did not
predict better glycaemic control across studies.
Conclusions: Limited evidence from short-to-medium
term RCTs predominantly conducted in the USA
suggests that collaborative care for depression
significantly improves both depression and glycaemia
outcomes, independently, in people with comorbid
depression and diabetes.
INTRODUCTION
Diabetes is currently ranked as the 14th
leading cause of global disease burden
(assessed using a summary measure of
healthy years of life lost due to premature
death and years lived with disability), and has
moved up several places in the rankings for
leading causes since 1990.1 The International
Diabetes Federation estimated that more than
371 million people (or 8.3% of the adult
population worldwide) had diabetes in 2012.2
Major depression, currently ranked the 11th
leading cause of global disease burden, has
also moved up several places in the rankings
for leading causes since 1990.1 Although
rankings varied substantially across regions,
healthcare practitioners in these countries
need guidance to better deal with the rising
burden of diabetes and depression.
Diabetes is a chronic physical health condi-
tion that is often comorbid with clinically rele-
vant symptoms of depression.3–5 Practitioners
should be aware that depression comorbidity
can signiﬁcantly worsen the self-care,6
health7–9 and economic burden of diabetes.10
This suggests that effective management of
depression in people with comorbid diabetes
could potentially reverse several of these
adverse outcomes, resulting in better gly-
caemic control among other beneﬁts.
The current National Institute for Health
and Care Excellence (NICE) guidelines for
depression in adults with a chronic physical
health problem, such as diabetes, recom-
mend collaborative care in a ‘stepped care
framework’ in which to organise health ser-
vices.11 Patients with an inadequate response
Strengths and limitations of this study
▪ The key findings were based on a high-quality
systematic review and meta-analysis level of
evidence.
▪ Since only a small number of short-to-medium
term studies predominantly conducted in the
USA were included, the findings of this review
may not be relevant to healthcare settings in
other countries, requiring further research.
▪ Collaborative care for depression significantly
improves depression and glycaemia outcomes in
people with comorbid depression and diabetes.
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to one or more treatments are ‘stepped up’ from low-
intensity care to a more intensive form of management
(including lifestyle, psychological and pharmacological
therapies). Practitioners should consider collaborative
care for patients with comorbid diabetes and depression,
since they typically need more intensive care.
Randomised controlled trial (RCT) evidence shows that
collaborative care is more effective than usual care for
improving depression outcomes both in the short and
longer terms in American primary care settings.12
Systematic reviews of RCTs have also conﬁrmed that collab-
orative care is more effective than usual care for improving
depression outcomes in people with comorbid dia-
betes,13 14 but there was a lack of consistent evidence for
improving glucose control.13 15 However, the results of
newly published RCTs suggest that collaborative care for
depression also leads to signiﬁcant improvements in gly-
caemic control.16 17 We therefore sought to systematically
assess the total body of RCTevidence on collaborative care
for depression in adults with comorbid depression and dia-
betes to inform guidelines and practice.
METHODS
Search strategy
We searched PubMed, Scopus, Cochrane Library,
CINAHL, Health Source Nursing, MEDLINE, PsychINFO
and reference lists of retrieved articles published before
August 2013. Search syntaxes were developed in consult-
ation with an experienced university research librarian
taking into account a broad range of terms and phrases
used in deﬁnitions of RCTs, collaborative care, depres-
sion and diabetes (full electronic search strategies for
PubMed and Scopus databases; online supplementary
appendix page 1). Reference lists of potentially eligible
articles were searched by hand to identify additional
studies missed by our search strategy.
Study selection
Two reviewers (EA and JF) identiﬁed potentially relevant
studies for inclusion by screening titles and/or abstracts
of all citations identiﬁed with our database searches. A
second screening was performed on the full text of
these articles. Articles for RCTs on collaborative care (ie,
evidence showing that the intervention was a coordi-
nated multidisciplinary model of care) for depression
that reported the effects on both depression and gly-
caemic outcomes in adults, most of who had to have
had comorbid diabetes, were eligible. There were no
language restrictions for articles.
Data extraction
Data extraction and quality assessment of included
studies were performed and/or veriﬁed independently
by three reviewers (EA, JF and PF). Discrepancies were
resolved through discussion. Authors of relevant studies
were contacted, where possible, for data that could not
be extracted from the published articles.
Quality assessment
For methodology and quality assessment, a quality check-
list was developed to identify potential sources of bias
(see online supplementary table; appendix page 2).
Quality items for RCTs reviewed were as follows (each
worth 1.0 numerical point): (1) study eligibility criteria
were adequately described, (2) randomisation method-
ology was adequate (ie, evidence suggesting a ‘random’
method was used to generate and implement the
random allocation sequence), (3) allocation conceal-
ment was adequate (ie, evidence to suggest that a robust
method was used for concealing the sequence of treat-
ment allocation (eg, independent IT or telephone
service or sealed opaque envelopes opened only in front
of the participant)), (4) between-group primary out-
comes were balanced at baseline (ie, evidence showing
that groups were similar at the outset for primary out-
comes), (5) between-group dropout rates were balanced
and (6) intention to treat analysis was included.
Our quality item checklist was designed based on cri-
teria for assessment of RCTs18 19 and allowed summed
scores to range from 0 to 6 points, reﬂecting lowest to
highest quality. Studies were considered ‘better quality’
if they received a score higher than 4, since that meant
that they had most of our quality items.
Primary outcomes
Data on the mean difference in depression and glycated
haemoglobin (HbA1c) outcomes between the treatment
and control groups were extracted and pooled using
random effects meta-analysis. In one study,16 the post-
treatment means were derived from the within-group
changes and the control group SD carried forward from
the baseline values.20 Standardised mean differences
(SMDs) were calculated using Glass’s δ method.
Data synthesis
Three reviewers (EA, PF and JF) independently collated
and/or veriﬁed extracted data to present a descriptive
synthesis of important study characteristics and a quanti-
tative synthesis of effect estimates.
Statistical methods
We pooled and weighted studies ﬁrst using random
effects meta-analysis models, and second using ﬁxed
effects models for veriﬁcation.21 Results for HbA1c were
pooled to estimate the inverse variance weighted mean
difference (WMD), including the DerSimonian and
Laird 95% CI, between treatment and control groups.
In examining the effects of collaborative care treat-
ment on depression scores, the SMD from each RCT was
pooled to produce an overall estimate of effect, and
associated 95% CI, between the treatment and control
groups. We used meta-regression to test the hypothesis
that the SMD in depression score is a predictor of the
WMD in HbA1c level.
For each meta-analysis model, the degree of hetero-
geneity in WMD or SMD was assessed by visual
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inspection, the I2 statistic (moderate being <50%22) and
the χ2 test of goodness of ﬁt.23 Where evidence of het-
erogeneity was observed, we checked data extracted
from individual outlier studies, qualitatively investigated
reasons for their different results and explored the
effects of study exclusion in sensitivity analyses.
We also used sensitivity analysis to investigate the robust-
ness of the meta-analyses models. We variously excluded
lower quality studies (score of ≤4), one study conducted
outside the USA (Australia), studies that integrated dia-
betes care, studies that considered lifestyle risk factors and
studies of less than 1-year duration. Publication bias, which
reﬂects the tendency for smaller studies to be published in
the literature only when ﬁndings are positive, was assessed
visually using funnel plots.24 All calculations were per-
formed in Stata V.12 (StataCorp, College Station, Texas,
USA) using the ‘metan’, ‘metareg’ and ‘metafunnel’ com-
mands. Effects were considered statistically signiﬁcant
when the associated 95% CIs did not include zero and het-
erogeneity was considered statistically signiﬁcant when the
associated p value was less than 0.05.
RESULTS
Figure 1 presents a ﬂow chart summarising the identiﬁ-
cation of potentially relevant studies, and those included
and excluded. Our search strategy identiﬁed 264 cita-
tions after duplicates were removed. Of these, 246 cita-
tions were excluded after the ﬁrst screening of titles
and/or abstracts for inclusion and exclusion criteria,
leaving 18 citations for a second full-text screening. After
further assessment, 11 citations were excluded for
reasons listed in ﬁgure 1, leaving seven RCTs for ﬁnal
inclusion in the systematic review. Most studies were
excluded due to inadequate study design or intervention
(ie, did not qualify as a collaborative care model), and a
couple of studies were excluded for being redundant
duplicate citations and for having incomplete data avail-
able for extraction (list of excluded citations and
reasons; see online supplementary appendix pages 3–4).
Descriptive data synthesis
Table 1 presents the study characteristics of seven RCTs
included for review, which were published between 2004
and 2013. All studies except one25 were conducted in the
USA. Major inclusion criteria were various case deﬁnitions
of diabetes in ﬁve studies,16 26–29 diabetes and/or coronary
heart disease in two studies17 25 and comorbid clinically
relevant depression in all studies. Major exclusion criteria
were cognitive impairment in four studies,16 17 28 29
comorbid psychiatric disorder or suicidal ideation in four
studies,17 27–29 alcohol problems in two studies27 29 and
living in residential care in two studies,17 25 among others.
The sample sizes ranged from 58 to 417, resulting in a
total of 1895 participants for depression outcomes and
1556 participants for HbA1c outcomes across studies. The
mean age of the samples ranged from 54 to 71 years. All
the study samples contained both male and female
participants. Baseline mean depression scores ranged
from 15.6 to 19.7 by the CES-D 20,26 from 9.9 to 11.6 by
the Patient Health Questionnaire (PHQ)-916 25 and from
1.4 to 1.7 by the Symptom Checklist (SCL)-20.17 27–29
Baseline mean HbA1c levels ranged from 6.9% to 9.1%.
Deﬁning features of collaborative care models investigated
were a case manager/ofﬁcer (usually a nurse or non-
physician mental health worker for coordination of care)
with proactive follow-ups in all studies, a structured man-
agement plan delivered within a stepped care framework
and relapse prevention in four studies,17 27–29 an inte-
grated diabetes care programme in three studies16 17 26
and consideration for lifestyle risk factors in two
studies.17 25 Control conditions were ‘usual care’ in four
studies,16 25 26 29 whereas usual care was enhanced in the
three other studies.17 27 28 Trial durations ranged from 12
to 52 weeks. Primary outcomes were depression score
assessed by the CES-D 20 in one study,26 by the PHQ-9 in
two studies16 25 and by the SCL-20 in four studies17 27–29;
and glycaemic control by HbA1c in all of the studies.
Mean quality scores ranged from 3.5 to 5.5, and all but
three studies25 26 29 received a score of 4.5 or higher.
Quantitative data synthesis
Effect of collaborative care on depression
Figure 2 presents the SMD in depression outcomes
after collaborative care between the treatment and
Figure 1 Flow chart summarising identification of studies
included for review. HbA1c, glycated haemoglobin;
randomised controlled trial (RCT).
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Table 1 Characteristics of randomised controlled trials reviewed
Study












(any) Treated Controls Treated Controls
Bogner et al26 USA 58 Aged ≥50 years, recent
HbA1c >7 or an oral
hypoglycaemic prescription
within the past year,
diagnosed depression or
an antidepressant
prescription within the past
year
None specified 16; 60 15.6 19.7 7.3 7.3
Bogner et al16 USA 180 Aged ≥30 years, diagnosis








in care facility providing
medications, unwillingness or
inability to use the Medication
Event Monitoring System
32; 57 10.6 9.9 7.2 7.0
Ell et al 27* USA 387 Aged ≥18 years, ‘with
diabetes’, one of two
cardinal depressive
symptoms most days and
depression score ≥10 by
the PHQ-9, informed
consent
Acute suicidal ideation, score
of ≥8 by the Alcohol Use
Disorders Identification Test,
inability to speak Spanish or
English
18; 54 1.7 1.4 9.0 9.1
Katon et al 28* USA 329 Diabetes (by registry),
depression score of ≥10
by the PHQ-9 at first
screening and score of







enrolment in the clinic
during the next year




















































(any) Treated Controls Treated Controls
Katon et al 17 USA 214 Diabetes, coronary heart
disease or both (by
registry), depression score
of ≥3 by the PHQ-2 and
≥10 by the PHQ-9,
ambulatory, spoke English
and planned to be enrolled
in the Health Maintenance
Organization for 12 months








current antipsychotic or mood
stabiliser medications,
symptoms of dementia
48; 57 1.7 1.7 8.1 8.0
Morgan et al 25 Australia 156 (glycaemia); 310
(depression)
Type 2 diabetes, coronary
heart disease or both (by
registry), depression score
of ≥5 by the PHQ-9,
informed consent
Aged <18 years, in residential
care
55; 68 10.7 11.6 7.0 6.9
Williams et al 29* USA 232 (glycaemia); 417
(depression)
Diagnosed or treated
diabetes or high blood







(score of ≥2 by the CAGE
questionnaire), history of
bipolar disorder or psychosis,
ongoing psychiatric care, or
severe cognitive impairment
(score of <3 by questionnaire)








‘Integrated care’; consisted of supervised case manager,
patient-centred care, education and integrated care for
depression and diabetes; three 30 min sessions in person
and two 15 min telephone follow-up sessions over 4 weeks




‘Integrated care’; consisted of supervised case manager,
patient-centred care, education and integrated care for
depression and diabetes; three 30 min sessions in person
and two 15 min telephone follow-up sessions over 3 months









































‘Collaborative care’; consisted of supervised nurse case
manager, patient-centred care, problem solving therapy,
self-monitoring education, and coordination of care and
services for depression and diabetes within a stepped-care
framework; monthly telephone symptom monitoring,
treatment maintenance and relapse prevention up to
12 months
‘Enhanced usual care’; and patient and





‘Collaborative care’; consisted of supervised nurse case
manager, patient-centred care (initial choice of
antidepressant or problem solving therapy), within a
stepped-care framework; initial one hour visit, followed by
twice monthly half-hour follow-ups (telephone or in-person)
up to 12 weeks and referral to specialty care thereafter if
necessary






‘Collaborative care’; consisted of supervised nurse case
manager, ‘treat-to-target program’ integrated care for specific
conditions, within a stepped-care framework, motivational
problem solving and goal setting for self-care (including
exercise, and ‘The Depression Helpbook’, video and written
material); structured visits every two to 3 weeks, and
maintenance plan once targeted levels were achieved
including telephone follow-ups every 4 weeks
‘Enhanced usual care’; patients could self-refer to
mental healthcare or be referred by primary care





‘Collaborative care’; consisted of collaborative care trained
nurse case manager, 45 min nurse consult every 3 months
followed (for assessment of lifestyle, physical and
biochemical risk factors, and referrals, self-care of
depression and setting personal goals for review and
discussion of educational resources), followed by a 15 min
consult with their usual general practitioner




Collaborative care; consisted of trained nurse or
psychologist case manager, patient-centred care, problem
solving therapy, 20 min educational video tape and written
material on late-life depression and coordination of care and
services for depression within a stepped-care framework;
monthly telephone symptom monitoring, treatment
maintenance and relapse prevention up to 12 months;
diabetes care not specifically enhanced




*Raw data were provided by the author.
CES-D, Center for Epidemiological Studies Depression scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; HbA1c, glycated haemoglobin; PHQ, Patient Health






























control groups. Collaborative care signiﬁcantly
improved standardised depression outcomes com-
pared with control conditions (pooled SMD was
−0.32 (95% CI −0.53 to −0.11)). There was statistical
heterogeneity between studies (I2=79%, p<0.001) that
was mostly a result of variation in the degree of
beneﬁt favouring collaborative care in all but one
study,27 which had signiﬁcant between-group differ-
ences in mean depression scores at baseline.
Correcting for these differences substantially changed
the SMD for that study (from 0.00 (95% CI −0.20 to
0.20) to −0.60 (95% CI −0.81 to −0.39)) in a sensitiv-
ity analysis. In addition, the sensitivity analyses pre-
sented in table 2 show that the pooled SMD was
substantially changed only after exclusion of lower
quality studies (decreased to −0.17 (95% CI −0.35 to
0.00)). A funnel plot was produced and conﬁrmed
widespread heterogeneity of effect estimates between
studies, but did not suggest any publication bias (see
online supplementary appendix page 5).
Effect of collaborative care on HbA1c
Figure 3 presents the WMD in HbA1c level after collab-
orative care between the treatment and control groups.
Collaborative care signiﬁcantly reduced the HbA1c level
compared with control conditions (pooled WMD was
−0.33% (95% CI −0.66% to −0.00%)). There was statis-
tical heterogeneity between studies (I2=72.9%,
p=0.001) that was mostly a result of variation in the
degree of beneﬁt favouring collaborative care in all
but two studies.28 29 The sensitivity analyses presented
in table 3 shows that the pooled WMD was slightly
decreased in the ﬁxed effect model (−0.21 (95% CI
−0.37 to −0.05)), but no longer statistically signiﬁcant
after each of the various studies was excluded. This
was particularly so after exclusion of three studies that
integrated diabetes care (decreased to −0.07 (95% CI
−0.35 to 0.21)). A funnel plot was produced and con-
ﬁrmed widespread heterogeneity of effect estimates
between studies, but did not suggest any publication
bias (see online supplementary appendix page 6).
Effect of depression remission on HbA1c
Figure 4 presents a scatter plot displaying the association
between the SMD in depression outcomes and the
WMD in HbA1c values in each study. Results of a
meta-regression model suggest that the SMD for depres-
sion scores failed to predict the WMD in HbA1c values
across studies (p=0.828, coefﬁcient was 0.19 (95% CI
−1.93 to 2.31)).




sample SMD 95% CI
p Value for
heterogeneity
Fixed effects model 7 1895 −0.31 (−0.40 to −0.22) <0.001
Exclusion of 3 lower quality studies (score ≤4.0) 4 1110 −0.17 (−0.35 to 0.00) 0.101
Exclusion of 1 study outside the USA (Australia) 6 1585 −0.32 (−0.57 to 0.07) <0.001
Exclusion of 3 studies that integrated diabetes care 4 1443 −0.30 (−0.62 to 0.01) <0.001
Exclusion of 2 studies that considered lifestyle risk
factors
5 1371 −0.30 (−0.59 to 0.00) <0.001
Exclusion of 4 studies of less than 1 year duration 3 1018 −0.34 (−0.68 to 0.01) <0.001
SMD, standardised mean difference.
Figure 2 Standardised mean
difference (SMD) in depression
outcomes after collaborative care
between the treatment and
control groups.
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DISCUSSION
Summary of evidence
On the basis of the limited evidence from
short-to-medium term RCTs predominantly conducted
in the USA, our results suggest that collaborative care
for depression signiﬁcantly improves depression and gly-
caemia outcomes in people with comorbid depression
and diabetes. Our results for better glycaemic control
are novel and more comprehensive than those pub-
lished from previous meta-analyses because we sought
and obtained raw unpublished data from the authors of
three studies.27–29 Furthermore, we found evidence from
a sensitivity analysis that future high-quality RCTs30 will
likely strengthen rather than weaken this evidence base.
The size of the effect of collaborative care on depression
and HbA1c outcomes that can be expected in practice is
small to moderate, but comparable with pharmaco-
logical, psychological and behavioural therapies
alone,13 14 31 32 and likely to be clinically relevant. For
instance, several of the RCTs we reviewed have also
shown that collaborative care for depression in people
with comorbid diabetes is more effective than usual care
for improving functional health outcomes33 and were
cost effective,34 35 consistent with previous economic
modelling.36 In addition, a recent meta-analysis found a
positive dose–response trend between the HbA1c level
and adverse cardiovascular outcomes.37 This suggests
that improvements in glycaemic control from collabora-
tive care for depression could theoretically protect
patients with comorbid diabetes against future cardiovas-
cular risk.
In contrast, we found no evidence to suggest that
improved depression outcomes result in better glycaemic
control (lower HbA1c values) among people with
comorbid diabetes. This null ﬁnding for reversibility of the
effect of depression on glycaemia weakens the evidence
base for causality in terms of worsening the burden of dia-
betes. Alternatively, collaborative care for depression may
improve glycaemia in people with diabetes by increasing
self-management, independent of the depression progno-
sis. For example, collaborative care for depression17 was
more effective than usual care for improving blood pres-
sure and blood glucose self-monitoring rates.38 Quality
improvement strategies for diabetes care that promote
glucose self-monitoring among patients can signiﬁcantly
improve the HbA1c level (SMD was 0.57% (0.31% to
0.83)).39 Indeed, evidence from our sensitivity analysis
showed that the effect of collaborative care on HbA1c was




of sample WMD 95% CI
p Value for
heterogeneity
Fixed effects model 7 1556 −0.21 (−0.37 to −0.05) 0.001
Exclusion of three lower quality studies (score ≤4.0) 4 1110 −0.32 (−0.81 to 0.17) 0.001
Exclusion of one study outside the USA (Australia) 6 1400 −0.31 (−0.68 to 0.07) 0.001
Exclusion of three studies that integrated diabetes care 4 1104 −0.07 (−0.35 to 0.21) 0.086
Exclusion of two studies that considered lifestyle risk
factors
5 1186 −0.27 (−0.71 to 0.16) 0.002
Exclusion of four studies of less than 1 year duration 3 833 −0.18 (−0.48 to 0.11) 0.189
HbA1c, glycated haemoglobin; WMD, weighted mean difference.
Figure 3 Weighted mean
difference (WMD) in glycated
haemoglobin level after
collaborative care between the
treatment and control groups.
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almost entirely conﬁned to the three studies that inte-
grated diabetes care within the collaborative care
model.16 17 26 Second, none of the RCTs that we reviewed
properly integrated the lifestyle intervention, as per the
current global guideline for effective management of type
2 diabetes,40 within the collaborative care. In high-income
countries such as the USA and Australia, depression is
associated with overweight or obesity, physical inactivity,
smoking cigarettes and drinking excessive amounts of
sugar-sweetened and alcoholic beverages,41 42 all of which
are well-established lifestyle risk factors for diabetes.
Indeed, there is international consensus supporting the
effectiveness of lifestyle intervention in the prevention and
management of type 2 diabetes.40 In addition, previous sys-
tematic reviews of RCTs have shown that exercise (an inte-
gral component of lifestyle intervention) is effective for
improving the depression score (SMD was −0.82 (95% CI
−1.12 to −0.51)) and HbA1c level (WMD was −0.67%
(95% CI −0.84% to −0.49%)),43 44 and the size of these
effects is substantially larger than what we found for collab-
orative care for depression. There is now sufﬁcient evi-
dence to suggest that diabetes care and lifestyle
intervention integrated within collaborative care for
depression would be the most effective way to manage
care for comorbid depression and diabetes.
Limitations
Several limitations require further consideration. Since only a
small number of short-to-medium term studies predomin-
antly conducted in the USA were included, the ﬁndings of
this review may not be relevant to healthcare settings in
other countries, requiring further research. In particular,
healthcare systems in most countries are not properly set up
to optimise the coordination between practitioners.45
Integration of therapies including collaborative care, diabetes
care and lifestyle intervention is required to effectively
manage comorbid depression diabetes. Second, the baseline
mean HbA1c level was close to the upper limit of the normal
range in several studies, which would have underestimated
the effect size for, and therapeutic beneﬁt of, collaborative
care for glycaemic control. Finally, reviewer-level limitations
include incomplete retrieval of information for several of the
11 citations excluded, and the existence of other relevant
studies not identiﬁed with our search strategy resulting in
bias. However, the results and conclusions reported in most
of the excluded studies were in line with those reported
here, and therefore search strategy bias was unlikely.
Conclusions
The limited evidence from short-to-medium term RCTs
predominantly conducted in the USA suggests that col-
laborative care for depression signiﬁcantly improves
depression and glycaemia outcomes, independently, in
people with comorbid depression and diabetes. Future
research should investigate the effectiveness, feasibility
and appropriateness of collaborative care integration
with diabetes care and lifestyle intervention for
comorbid depression and diabetes, and other comorbid
cardiovascular risk conditions, in routine clinical prac-
tice in speciﬁc healthcare settings worldwide.
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